Titre:
  • An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
Auteur:Awada, Ahmad; Thödtmann, R; Piccart-Gebhart, Martine; Wanders, Jantien; Schrijvers, A H G J; Von Broen, I-M; Hanauske, Axel-R; EORTC-ECSG phase I study,
Informations sur la publication:European journal of cancer, 39, 6, page (742-747)
Statut de publication:Publié, 2003-04
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adult
Aged
Amides -- administration & dosage
Amides -- adverse effects
Amides -- pharmacokinetics
Antineoplastic Agents -- administration & dosage
Antineoplastic Agents -- adverse effects
Antineoplastic Agents -- pharmacokinetics
Cohort Studies
Drug Administration Schedule
Female
Half-Life
Humans
Infusions, Intravenous
Isoquinolines -- administration & dosage
Isoquinolines -- adverse effects
Isoquinolines -- pharmacokinetics
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms -- drug therapy
Note générale:Clinical Trial
Clinical Trial, Phase I
Journal Article
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:pii/S0959804902007761
info:pmid/12651198